Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.61 |
| ▸ | POU2F2 | P09086 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | POU2F1 | P14859 | 1/20 | 0.58 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.58 |
| ▸ | HRH2 | P25021 | 1/20 | 0.58 |
| ▸ | MC4R | P32245 | 1/20 | 0.58 |
| ▸ | FAP | Q12884 | 1/20 | 0.58 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.58 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.58 |
| ▸ | GHSR | Q92847 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19154444 | 0.93 | DPP4 (0.61) | DPP4CHRM1POU2F2ADORA3POU2F1 | |
| SCHEMBL195762 | 0.92 | DPP4 (0.74) | DPP4CHRM1POU2F2ADORA3POU2F1 | |
| SCHEMBL195761 | 0.92 | DPP4 (0.74) | DPP4CHRM1POU2F2ADORA3POU2F1 | |
| SCHEMBL24509039 | 0.90 | DPP4 (0.61) | DPP4CHRM1POU2F2ADORA3POU2F1 | |
| SCHEMBL18708107 | 0.89 | DPP4 (0.58) | DPP4CHRM1 | |
| SCHEMBL13945340 | 0.87 | DPP4 (0.51) | DPP4CHRM1 | |
| SCHEMBL13945565 | 0.86 | DPP4 (0.49) | DPP4CHRM1 | |
| SCHEMBL685384 | 0.86 | DPP4 (0.84) | DPP4 | |
| SCHEMBL8206959 | 0.86 | DPP4 (0.54) | DPP4 | |
| SCHEMBL2609251 | 0.86 | DPP4 (0.68) | DPP4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2990037-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | Boehringer Ingelheim International GmbH (DE) | 2016-03-02 | — | — | EP | disclosed |
| US-20120165251-A1 | Diabetes therapy | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | US | disclosed |
| US-20110301182-A1 | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-08 | — | — | US | disclosed |
| US-20110263617-A1 | Combination therapy for the treatment of diabetes and related conditions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110112069-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-12 | — | — | US | disclosed |
| US-20110098240-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A SGLT2 INHIBITOR IN COMBINATION WITH A DPP-IV INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-28 | — | — | US | disclosed |
| US-20110092510-A1 | DPP-IV INHIBITORS FOR USE IN THE TREATMENT OF NAFLD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-21 | — | — | US | disclosed |
| US-20110065731-A1 | USES OF DPP-IV INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092510-A1 | DPP-IV INHIBITORS FOR USE IN THE TREATMENT OF NAFLD | DPP4, DPP3, DPP7 | DPP4 1/4885CHRM1 3696/4885POU2F2 3277/4885 |
| US-20120165251-A1 | Diabetes therapy | DPP4, DPP3, DPP7 | DPP4 1/4885CHRM1 2895/4885POU2F2 2348/4885 |
| US-20110065731-A1 | USES OF DPP-IV INHIBITORS | DPP4, DPP3, DPP7 | DPP4 1/4885CHRM1 2215/4885POU2F2 3160/4885 |
| US-20110301182-A1 | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor | DPP4, DPP3, DPP7 | DPP4 1/4885CHRM1 4759/4885POU2F2 981/4885 |
| US-20110263617-A1 | Combination therapy for the treatment of diabetes and related conditions | GPR119, DPP4, GLP1R | DPP4 2/4885CHRM1 3049/4885POU2F2 1737/4885 |
| US-20110098240-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A SGLT2 INHIBITOR IN COMBINATION WITH A DPP-IV INHIBITOR | SLC5A1, SLC5A2, DPP4 | DPP4 3/4885CHRM1 3573/4885POU2F2 2807/4885 |
| US-20110112069-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | PNP, PURB, NUDT14 | DPP4 3263/4885CHRM1 4301/4885POU2F2 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.